{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T13:34:28Z","timestamp":1767792868255,"version":"3.49.0"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["209740"],"award-info":[{"award-number":["209740"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,11,25]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction\/Aim<\/jats:title>\n                    <jats:p>Lung inhomogeneity measures obtained using computed cardiopulmonography (CCP) are sensitive to small-airways disease. Here, we assessed changes in lung inhomogeneity in patients with type-2 high asthma treated with biological therapy and explored the relationship between inhomogeneity measures and conventional asthma disease markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational study of 91 severe type-2 high asthma patients recruited from a tertiary asthma clinic, of whom 67 subsequently started anti-IL5 or anti-IL5R biologics. Patients were evaluated at baseline and, 54 of those commencing biologics, at their fourth injection with either mepolizumab or benralizumab. Assessments included prebronchodilator and postbronchodilator CCP and spirometry, and measurements of blood eosinophil count (BEC), fractional exhaled nitric oxide and Asthma-Symptom Questionnaire (ACQ-5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Bronchodilation significantly reduced \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      , a novel CCP-derived ventilation inhomogeneity index, (\u0394\u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      \u22120.08, 95%\u2009CI (\u22120.10 to \u20130.05), p&lt;0.001). Baseline \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      , but not forced expiratory volume in 1 s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) % predicted, was significantly associated with BEC (linear mixed-effects (LME) regression coefficient for BEC 0.18, 95%\u2009CI (0.04, 0.32), p=0.01). Following biologics, improvements in \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      were significantly dependent on BEC (LME regression coefficient +0.19, 95%\u2009CI (0.11, 0.27), p&lt;0.001) whereas improvements in FEV\n                      <jats:sub>1<\/jats:sub>\n                      % predicted related to both BEC and ACQ-5 responses (LME coefficients: BEC \u221210.8 % pred, 95%\u2009CI (\u221216.1,\u20135.5); ACQ-5 \u20133.5 % pred, 95%\u2009CI (\u22125.1 to \u20131.9), p&lt;0.001). Following biologics, the change in \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      followed a bimodal distribution that dichotomised patients into \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      -Responders and \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      -Non-Responders. Responders, unlike Non-Responders, experienced significant improvements in symptoms and FEV\n                      <jats:sub>1<\/jats:sub>\n                      % predicted (\u0394 pre-BD FEV\n                      <jats:sub>1<\/jats:sub>\n                      15\u00b115% pred, p&lt;0.001) and included a higher proportion of patients in clinical remission at 1 year.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      is strongly associated with systemic eosinophilic inflammation in severe type-2 high asthma. An early \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      response following anti-IL5 biologics identifies patients more likely to experience improvements in symptoms and lung function when systemic eosinophils are depleted. \u03c3lnC\n                      <jats:sc>l<\/jats:sc>\n                      may provide a sensitive route for tracking inflammation involving the small airways.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002721","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:50:21Z","timestamp":1739015421000},"page":"e002721","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of biologic therapy on novel indices of lung inhomogeneity in patients with severe type-2 high asthma"],"prefix":"10.1136","volume":"12","author":[{"given":"Asma","family":"Alamoudi","sequence":"first","affiliation":[{"name":"Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK"},{"name":"Department of Respiratory Care, Prince Sultan Military College of Health Sciences, Dhahran, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Petralia","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford, UK"},{"name":"University of Innsbruck Breath Research Institute, Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3206-9793","authenticated-orcid":false,"given":"Nicholas M J","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haopeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-5067","authenticated-orcid":false,"given":"Graham","family":"Richmond","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-8950","authenticated-orcid":false,"given":"Nick P","family":"Talbot","sequence":"additional","affiliation":[{"name":"Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK"},{"name":"Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-7770","authenticated-orcid":false,"given":"Grant AD","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4975-0609","authenticated-orcid":false,"given":"Peter A","family":"Robbins","sequence":"additional","affiliation":[{"name":"Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5524-020X","authenticated-orcid":false,"given":"Nayia","family":"Petousi","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, Oxford, UK"},{"name":"Oxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"2026010701501639000_12.1.e002721.1","unstructured":"Societies FoIR . The Global Impact of Respiratory Disease. 2nd edn. 2017."},{"key":"2026010701501639000_12.1.e002721.2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212441"},{"key":"2026010701501639000_12.1.e002721.3","doi-asserted-by":"publisher","DOI":"10.1080\/02770900500294678"},{"key":"2026010701501639000_12.1.e002721.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30879-6"},{"key":"2026010701501639000_12.1.e002721.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2026010701501639000_12.1.e002721.6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026010701501639000_12.1.e002721.7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1152\/japplphysiol.00436.2022","article-title":"Altered lung physiology in two cohorts after COVID-19 infection as assessed by computed cardiopulmonography","volume":"133","author":"Magor-Elliott","year":"2022","journal-title":"J Appl Physiol"},{"key":"2026010701501639000_12.1.e002721.8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1152\/japplphysiol.00745.2017","article-title":"Potential for noninvasive assessment of lung inhomogeneity using highly precise, highly time-resolved measurements of gas exchange","volume":"124","author":"Mountain","year":"2018","journal-title":"J Appl Physiol"},{"key":"2026010701501639000_12.1.e002721.9","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.1032126","article-title":"The Lognormal Lung: A new approach to quantifying lung inhomogeneity in COPD","volume":"13","author":"Smith","year":"2022","journal-title":"Front Physiol"},{"key":"2026010701501639000_12.1.e002721.10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1152\/japplphysiol.00744.2022","article-title":"Computed cardiopulmonography and the idealized lung clearance index, iLCI 2.5, in early-stage cystic fibrosis","volume":"135","author":"Sandhu","year":"2023","journal-title":"J Appl Physiol"},{"key":"2026010701501639000_12.1.e002721.11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2024.02.006","article-title":"Computed Cardiopulmonography for the Detection of Early Smoking-Related Changes in the Lungs of Young Individuals Who Smoke","volume":"165","author":"Redmond","year":"2024","journal-title":"Chest"},{"key":"2026010701501639000_12.1.e002721.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2019-000531","article-title":"Novel measure of lung function for assessing disease activity in asthma","volume":"7","author":"Smith","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"2026010701501639000_12.1.e002721.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202109-2205PP"},{"key":"2026010701501639000_12.1.e002721.14","unstructured":"NICE . Mepolizumab for treating severe eosinophilic asthma. 2021."},{"key":"2026010701501639000_12.1.e002721.15","unstructured":"NICE . Benralizumab for treating severe eosinophilic asthma. 2019."},{"key":"2026010701501639000_12.1.e002721.16","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600560","article-title":"In-airway molecular flow sensing: A new technology for continuous, noninvasive monitoring of oxygen consumption in critical care","volume":"2","author":"Ciaffoni","year":"2016","journal-title":"Sci Adv"},{"key":"2026010701501639000_12.1.e002721.17","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"2026010701501639000_12.1.e002721.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.609"},{"key":"2026010701501639000_12.1.e002721.19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rmed.2016.05.006","article-title":"The prevalence of small airways disease in adult asthma: A systematic literature review","volume":"116","author":"Usmani","year":"2016","journal-title":"Respir Med"},{"key":"2026010701501639000_12.1.e002721.20","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(19)30049-9"},{"key":"2026010701501639000_12.1.e002721.21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00536-1"},{"key":"2026010701501639000_12.1.e002721.22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1152\/japplphysiol.00103.2022","article-title":"Small airways dysfunction is associated with increased exacerbations in patients with asthma","volume":"133","author":"O\u2019Sullivan","year":"2022","journal-title":"J Appl Physiol"},{"key":"2026010701501639000_12.1.e002721.23","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1382"},{"key":"2026010701501639000_12.1.e002721.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03496-6"},{"key":"2026010701501639000_12.1.e002721.25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JAA.S78049","article-title":"Benralizumab: a unique IL-5 inhibitor for severe asthma","volume":"9","author":"Tan","year":"2016","journal-title":"J Asthma Allergy"},{"key":"2026010701501639000_12.1.e002721.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.01.016"},{"key":"2026010701501639000_12.1.e002721.27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"2026010701501639000_12.1.e002721.28","doi-asserted-by":"crossref","first-page":"101899","DOI":"10.1016\/j.pupt.2020.101899","article-title":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","volume":"61","author":"Sposato","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"2026010701501639000_12.1.e002721.29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9111550","article-title":"Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma","volume":"9","author":"Maglio","year":"2021","journal-title":"Biomedicines"},{"key":"2026010701501639000_12.1.e002721.30","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701501639000_12.1.e002721.31","doi-asserted-by":"crossref","first-page":"110444","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2026010701501639000_12.1.e002721.32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/all.13938","article-title":"Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma","volume":"75","author":"Antonicelli","year":"2020","journal-title":"Allergy"},{"key":"2026010701501639000_12.1.e002721.33","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.jaip.2021.01.029","article-title":"Real-life small airway outcomes in severe asthma patients receiving biologic therapies","volume":"9","author":"Chan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026010701501639000_12.1.e002721.34","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1111\/all.14339","article-title":"Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma","volume":"75","author":"Shirai","year":"2020","journal-title":"Allergy"},{"key":"2026010701501639000_12.1.e002721.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.008"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:50:35Z","timestamp":1767779435000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,8]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjresp-2024-002721"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002721","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}